Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Roche's oral SERD flunks 1st-line breast cancer phase 3
The trial missed its primary endpoint, tarnishing the record of a drug candidate that hit the mark in adjuvant and second-line settings.
Nick Paul Taylor
Mar 9, 2026 6:40am
CBER Director Vinay Prasad to depart FDA—again
Mar 6, 2026 5:30pm
How physiology powers biotech innovation
Brought to you by
American Physiological Society
Vertex races to FDA after phase 3 kidney disease data impress
Mar 10, 2026 6:20am
AI could spot heart disease in breast cancer mammograms
Mar 9, 2026 2:25pm
BMS' CELMoD drug improves myeloma PFS in phase 3
Mar 9, 2026 11:08am
More News
Xenon epilepsy candidate 'blows away' ph. 3 expectations
Mar 9, 2026 10:55am
FDA greenlights backup anti-choking suction device
Mar 9, 2026 10:45am
Tenacia pens $308M Rapport deal for China rights to epilepsy med
Mar 9, 2026 10:30am
AbbVie ties $350M bet to almost 10% weight loss after 12 weeks
Mar 9, 2026 9:50am
See more stories